🇺🇸 ranibizumab 0.5 mg in United States

14 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Cardiac Failure Congestive — 3 reports (21.43%)
  2. Dizziness — 2 reports (14.29%)
  3. Nausea — 2 reports (14.29%)
  4. Asthenia — 1 report (7.14%)
  5. Bladder Cancer — 1 report (7.14%)
  6. Blood Pressure Systolic Increased — 1 report (7.14%)
  7. Chronic Obstructive Pulmonary Disease — 1 report (7.14%)
  8. Coronary Artery Disease — 1 report (7.14%)
  9. Dehydration — 1 report (7.14%)
  10. Hypertension — 1 report (7.14%)

Source database →

ranibizumab 0.5 mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ranibizumab 0.5 mg approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for ranibizumab 0.5 mg in United States?

Novartis Pharmaceuticals is the originator. The local marketing authorisation holder may differ — check the official source linked above.